August 25, 2017 / 4:11 PM / a month ago

BRIEF-U.S. FDA approves CV label for Novo's diabetes drug Victoza‍​

Aug 25 (Reuters) - U.S. Food and Drug Administration:

* Approved new indication for Victoza (liraglutide) to reduce risk of major adverse cardiovascular events in adults with type 2 diabetes, cv disease‍​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below